Victory Capital Management Inc. decreased its position in Codexis, Inc. (NASDAQ:CDXS) by 3.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 96,170 shares of the biotechnology company’s stock after selling 3,830 shares during the quarter. Victory Capital Management Inc. owned about 0.18% of Codexis worth $1,606,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Codexis by 5.2% during the third quarter. BlackRock Inc. now owns 3,579,527 shares of the biotechnology company’s stock worth $61,389,000 after purchasing an additional 176,952 shares during the period. Baillie Gifford & Co. increased its position in Codexis by 5.9% in the 3rd quarter. Baillie Gifford & Co. now owns 2,801,237 shares of the biotechnology company’s stock worth $48,041,000 after purchasing an additional 154,997 shares during the last quarter. Vanguard Group Inc increased its position in Codexis by 7.8% in the 3rd quarter. Vanguard Group Inc now owns 2,267,934 shares of the biotechnology company’s stock worth $38,895,000 after purchasing an additional 164,817 shares during the last quarter. Vanguard Group Inc. increased its position in Codexis by 7.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,267,934 shares of the biotechnology company’s stock worth $38,895,000 after purchasing an additional 164,817 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Codexis by 35.8% in the 3rd quarter. Wells Fargo & Company MN now owns 1,826,947 shares of the biotechnology company’s stock worth $31,332,000 after purchasing an additional 481,273 shares during the last quarter. Institutional investors and hedge funds own 83.26% of the company’s stock.
CDXS stock opened at $20.91 on Friday. The firm has a market cap of $1.18 billion, a P/E ratio of -99.57 and a beta of -0.37. Codexis, Inc. has a fifty-two week low of $9.10 and a fifty-two week high of $23.05.
Several research analysts have weighed in on CDXS shares. BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a research report on Friday, November 2nd. HC Wainwright set a $17.00 target price on Codexis and gave the stock a “buy” rating in a research report on Monday, November 12th. Stephens upped their target price on Codexis from $16.00 to $25.00 and gave the stock an “overweight” rating in a research report on Monday, December 10th. Jefferies Financial Group upped their target price on Codexis from $4.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 15th. Finally, First Analysis upgraded Codexis from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $12.00 to $19.00 in a research note on Thursday, January 17th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $20.21.
In other Codexis news, CFO Gordon Sangster sold 75,000 shares of Codexis stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $16.94, for a total transaction of $1,270,500.00. Following the transaction, the chief financial officer now directly owns 169,453 shares in the company, valued at $2,870,533.82. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Dennis P. Wolf sold 9,000 shares of Codexis stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $21.96, for a total value of $197,640.00. The disclosure for this sale can be found here. Insiders sold a total of 242,227 shares of company stock worth $4,480,212 over the last quarter. Corporate insiders own 11.40% of the company’s stock.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Further Reading: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.